RA
UNCY icon

Rosalind Advisors’s Unicycive Therapeutics UNCY Stock Holding History

Rosalind Advisors’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-157,120
Closed -$787K – 40
2024
Q2 		$787K Sell
157,120
-30,845
-16% -$303K 0.61% 29
2024
Q1 		$2.59M Buy
+187,965
New +$2.28M 2.42% 18

Other funds holding UNCY

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Rosalind Advisors's UNCY Position: Q3 2024 in Review

Rosalind Advisors sold out of Unicycive Therapeutics (UNCY) in Q3 2024, closing a stake of 157,120 shares — an estimated $787K sold.

Rosalind Advisors first reported a position in UNCY in Q1 2024 and held it in 2 quarters. The position peaked at $2.59M in Q1 2024. 28 funds tracked by Wall St. Rank hold UNCY as of Q3 2024.

  • Rosalind Advisors reported no remaining Unicycive Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Rosalind Advisors sold 157,120 Unicycive Therapeutics shares in Q3 2024, an estimated $787K.
  • Rosalind Advisors first reported a position in Unicycive Therapeutics in Q1 2024 and held it in 2 quarters.
  • Rosalind Advisors's Unicycive Therapeutics position peaked at $2.59M in Q1 2024.
  • 28 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2024.

Based on Rosalind Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.